Brief: Brainstorm Cell Therapeutics To Provide Corporate Update On Phase 3b Trial At The 2024 Maxim Healthcare Virtual Summit
07/10/2024 12:08
Oct 7 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS TO PROVIDE CORPORATE UPDATE
ON
PHASE 3B NUROWN® TRIAL AT THE 2024 MAXIM HEALTHCARE VIRTUAL
SUMMIT
Source text for Eikon: ID:nPnv9fwFa
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview